Stem definition | Drug id | CAS RN |
---|---|---|
5227 | 1025504-45-3 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 1.31 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 18 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 11, 2017 | FDA | NEUROCRINE BIOSCIENCES INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Somnolence | 470.52 | 38.72 | 250 | 4721 | 154735 | 50445418 |
Drooling | 370.67 | 38.72 | 82 | 4889 | 3302 | 50596851 |
Tremor | 261.81 | 38.72 | 154 | 4817 | 114749 | 50485404 |
Parkinsonism | 256.30 | 38.72 | 74 | 4897 | 8773 | 50591380 |
Sedation | 229.98 | 38.72 | 93 | 4878 | 30517 | 50569636 |
Dyskinesia | 166.65 | 38.72 | 72 | 4899 | 27789 | 50572364 |
Hospitalisation | 143.72 | 38.72 | 87 | 4884 | 67850 | 50532303 |
Death | 107.53 | 38.72 | 145 | 4826 | 325234 | 50274919 |
Therapeutic product effect decreased | 107.35 | 38.72 | 96 | 4875 | 135954 | 50464199 |
Adverse drug reaction | 94.79 | 38.72 | 62 | 4909 | 55160 | 50544993 |
Balance disorder | 92.27 | 38.72 | 67 | 4904 | 70523 | 50529630 |
Therapeutic product effect incomplete | 91.41 | 38.72 | 74 | 4897 | 91441 | 50508712 |
Drug ineffective | 90.01 | 38.72 | 226 | 4745 | 819107 | 49781046 |
Restlessness | 85.32 | 38.72 | 44 | 4927 | 25129 | 50575024 |
Akathisia | 79.31 | 38.72 | 30 | 4941 | 8199 | 50591954 |
Urticaria | 62.39 | 38.72 | 70 | 4901 | 129491 | 50470662 |
Fall | 61.24 | 38.72 | 114 | 4857 | 334818 | 50265335 |
Anxiety | 56.63 | 38.72 | 78 | 4893 | 177528 | 50422625 |
Dizziness | 52.50 | 38.72 | 109 | 4862 | 346260 | 50253893 |
Feeling abnormal | 50.73 | 38.72 | 62 | 4909 | 125430 | 50474723 |
Bradykinesia | 47.70 | 38.72 | 17 | 4954 | 3926 | 50596227 |
Gait disturbance | 44.97 | 38.72 | 64 | 4907 | 149941 | 50450212 |
Fatigue | 44.60 | 38.72 | 161 | 4810 | 707440 | 49892713 |
Depression | 41.60 | 38.72 | 65 | 4906 | 165358 | 50434795 |
Nightmare | 40.22 | 38.72 | 23 | 4948 | 16063 | 50584090 |
Lethargy | 39.08 | 38.72 | 35 | 4936 | 49397 | 50550756 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drooling | 411.92 | 48.12 | 86 | 2540 | 2935 | 29568966 |
Somnolence | 269.43 | 48.12 | 141 | 2485 | 93814 | 29478087 |
Parkinsonism | 168.54 | 48.12 | 50 | 2576 | 7228 | 29564673 |
Tremor | 159.32 | 48.12 | 92 | 2534 | 73446 | 29498455 |
Sedation | 147.16 | 48.12 | 56 | 2570 | 17349 | 29554552 |
Hospitalisation | 100.55 | 48.12 | 58 | 2568 | 45930 | 29525971 |
Drug ineffective | 86.78 | 48.12 | 131 | 2495 | 363039 | 29208862 |
Therapeutic product effect decreased | 80.32 | 48.12 | 43 | 2583 | 29408 | 29542493 |
Adverse drug reaction | 62.47 | 48.12 | 34 | 2592 | 23986 | 29547915 |
Anxiety | 62.01 | 48.12 | 55 | 2571 | 85310 | 29486591 |
Death | 61.85 | 48.12 | 109 | 2517 | 341975 | 29229926 |
Fall | 58.54 | 48.12 | 75 | 2551 | 177103 | 29394798 |
Dyskinesia | 56.65 | 48.12 | 30 | 2596 | 20031 | 29551870 |
Restlessness | 53.87 | 48.12 | 30 | 2596 | 22115 | 29549786 |
Dizziness | 50.03 | 48.12 | 72 | 2554 | 189612 | 29382289 |
Therapeutic product effect incomplete | 49.37 | 48.12 | 35 | 2591 | 39270 | 29532631 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Somnolence | 439.84 | 35.97 | 244 | 4871 | 203401 | 64290216 |
Drooling | 420.92 | 35.97 | 95 | 5020 | 5224 | 64488393 |
Tremor | 271.67 | 35.97 | 160 | 4955 | 148070 | 64345547 |
Parkinsonism | 219.84 | 35.97 | 70 | 5045 | 14303 | 64479314 |
Sedation | 188.88 | 35.97 | 83 | 5032 | 41379 | 64452238 |
Hospitalisation | 147.41 | 35.97 | 85 | 5030 | 75122 | 64418495 |
Death | 146.87 | 35.97 | 185 | 4930 | 482520 | 64011097 |
Dyskinesia | 126.73 | 35.97 | 62 | 5053 | 39326 | 64454291 |
Anxiety | 105.16 | 35.97 | 103 | 5012 | 202546 | 64291071 |
Restlessness | 97.11 | 35.97 | 52 | 5063 | 39733 | 64453884 |
Fall | 84.79 | 35.97 | 132 | 4983 | 416694 | 64076923 |
Therapeutic product effect decreased | 84.02 | 35.97 | 71 | 5044 | 115280 | 64378337 |
Balance disorder | 81.09 | 35.97 | 61 | 5054 | 83865 | 64409752 |
Therapeutic product effect incomplete | 73.91 | 35.97 | 63 | 5052 | 103419 | 64390198 |
Fatigue | 67.28 | 35.97 | 168 | 4947 | 748562 | 63745055 |
Urticaria | 62.00 | 35.97 | 67 | 5048 | 147250 | 64346367 |
Dizziness | 61.99 | 35.97 | 117 | 4998 | 430046 | 64063571 |
Feeling abnormal | 61.98 | 35.97 | 64 | 5051 | 133538 | 64360079 |
Drug ineffective | 61.78 | 35.97 | 175 | 4940 | 840072 | 63653545 |
Lethargy | 55.51 | 35.97 | 46 | 5069 | 72548 | 64421069 |
Adverse drug reaction | 52.87 | 35.97 | 37 | 5078 | 45427 | 64448190 |
Akathisia | 48.97 | 35.97 | 22 | 5093 | 11488 | 64482129 |
Depression | 45.64 | 35.97 | 64 | 5051 | 183227 | 64310390 |
Gait disturbance | 44.19 | 35.97 | 61 | 5054 | 172094 | 64321523 |
Salivary hypersecretion | 41.72 | 35.97 | 20 | 5095 | 12093 | 64481524 |
Bradykinesia | 39.36 | 35.97 | 16 | 5099 | 6544 | 64487073 |
Insomnia | 37.72 | 35.97 | 61 | 5054 | 197775 | 64295842 |
None
Source | Code | Description |
---|---|---|
ATC | N07XX13 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
FDA MoA | N0000190855 | Vesicular Monoamine Transporter 2 Inhibitors |
FDA EPC | N0000190856 | Vesicular Monoamine Transporter 2 Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tardive dyskinesia | indication | 102449007 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.25 | Basic |
pKa2 | 7.56 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | April 11, 2022 | NEW CHEMICAL ENTITY |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | April 11, 2022 | NEW CHEMICAL ENTITY |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | April 11, 2022 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 8.52 | DRUG LABEL | DRUG LABEL | |||
Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 6.73 | IUPHAR |
ID | Source |
---|---|
54K37P50KH | UNII |
C4078701 | UMLSCUI |
CHEMBL2364639 | ChEMBL_ID |
24795069 | PUBCHEM_CID |
DB11915 | DRUGBANK_ID |
D10675 | KEGG_DRUG |
CHEMBL3707248 | ChEMBL_ID |
8694 | IUPHAR_LIGAND_ID |
14580381 | PUBCHEM_CID |
1918219 | RXNORM |
255701 | MMSL |
32624 | MMSL |
d08559 | MMSL |
733727001 | SNOMEDCT_US |
763512007 | SNOMEDCT_US |
4036639 | VANDF |
017167 | NDDF |
017168 | NDDF |
C000603978 | MESH_SUPPLEMENTAL_RECORD_UI |
9744 | INN_ID |
1639208-54-0 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 28 sections |
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 28 sections |
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 28 sections |